Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam… - Annals of …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
[HTML][HTML] Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam, SMR Huq - Annals of Medicine, 2022 - ncbi.nlm.nih.gov
Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
[PDF][PDF] Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam, S Mahmud… - Annals of …, 2020 - researchgate.net
Background: Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam, SMR Huq - Annals of Medicine, 2022 - europepmc.org
Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
[PDF][PDF] Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam… - ANNALS OF …, 2022 - scienceopen.com
Background: Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam, SMR Huq - Annals of Medicine, 2022 - europepmc.org
Background Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
[PDF][PDF] Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in …
MJ Hasan, R Rabbani, AM Anam, S Mahmud… - Annals of …, 2020 - researchgate.net
Background: Hyperinflammation-induced respiratory failure is a leading cause of mortality in
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …
COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are …